Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
' Graft vs Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market.
The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Graft vs Host Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years.
Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment
Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years.
In April 2025, The California Institute for Regenerative Medicine (CIRM) has granted $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103. This therapy aims to prevent graft-versus-host disease (GvHD) in blood cancer patients receiving mismatched stem cell transplants. TRX103 is an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to reduce transplant-related complications and improve patient outcomes.
In March 2025, Orca Bio's investigational T-cell immunotherapy for blood cancers significantly improved outcomes, more than doubling the rate of patients who remained free from moderate-to-severe chronic graft-versus-host disease (GvHD). According to results from the Phase III Precision-T trial (NCT05316701), 78% of patients treated with Orca-T (TRGFT-201), the company's lead allogeneic T-cell therapy, were GvHD-free after one year, compared to only 38% in the group receiving standard allogeneic stem cell transplants.
In January 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) aimed at improving survival outcomes in cancer patients through immune system modulation, has announced positive topline results from its pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter study conducted across Europe assessed the safety and efficacy of MaaT013 in patients with acute Graft-versus-Host Disease involving the gastrointestinal tract (GI-aGvHD) who are in third-line treatment — meaning they are resistant to steroids and either refractory or intolerant to ruxolitinib. The trial successfully achieved its primary endpoint, with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%. These outcomes, evaluated by an Independent Review Committee (IRC), exceeded the predefined efficacy threshold and underscore the strong clinical potential of MaaT013 in treating third-line GI-aGvHD.
In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft versus host disease (GvHD) in pediatric patients aged two months and older. Significantly, this marks the first FDA-approved MSC-based therapy. The treatment will be commercially available under the brand name Ryoncil.
Graft vs Host Disease Overview
Graft versus Host Disease (GvHD) is a medical condition that can occur after a stem cell or bone marrow transplant, where the donor's immune cells (graft) recognize the recipient's body (host) as foreign and attack it. GvHD commonly affects the skin, liver, and gastrointestinal tract. It is classified into acute and chronic forms, with symptoms ranging from mild rashes and diarrhea to severe organ damage. Management typically involves immunosuppressive therapies to reduce the immune response.
Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include:
ABSK021: Abbisko Therapeutics
SYN-004: Theriva Biologics
SER-155: Seres Therapeutics
CB103: Cellestia Biotech
Glasdegib: Pfizer
TQ 05105: Chia Tai Tianqing Pharmaceutical
RGI-2001: Regimmune Corporation
Axatilimab: Syndax Pharmaceuticals
MaaT013: MaaT Pharma
MC 0518: Medac
Itolizumab: Equillium
Elranatamab: Pfizer
Felzartamab: Janssen Pharmaceutical
T-Guard: Xenikos
MaaT013: MaaT Pharma
Axatilimab: Syndax Pharmaceuticals
TQ 05105: Chia Tai Tianqing Pharmaceutical Group
Graft vs Host Disease Route of Administration
Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Intravenous
Subcutaneous
Graft vs Host Disease Molecule Type
Graft vs Host Disease Products have been categorized under various Molecule types, such as
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Graft vs Host Disease Pipeline Therapeutics Assessment
Graft vs Host Disease Assessment by Product Type
Graft vs Host Disease By Stage and Product Type
Graft vs Host Disease Assessment by Route of Administration
Graft vs Host Disease By Stage and Route of Administration
Graft vs Host Disease Assessment by Molecule Type
Graft vs Host Disease by Stage and Molecule Type
DelveInsight's Graft vs Host Disease Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies
Some of the key companies in the Graft vs Host Disease Therapeutics Market include:
Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.
Graft vs Host Disease Pipeline Analysis:
The Graft vs Host Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment.
Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Graft vs Host Disease Pipeline Market Drivers
Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market.
Graft vs Host Disease Pipeline Market Barriers
However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth.
Scope of Graft vs Host Disease Pipeline Drug Insight
Coverage: Global
Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others
Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others
Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies
Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers
Table of Contents
1. Graft vs Host Disease Report Introduction
2. Graft vs Host Disease Executive Summary
3. Graft vs Host Disease Overview
4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment
5. Graft vs Host Disease Pipeline Therapeutics
6. Graft vs Host Disease Late Stage Products (Phase II/III)
7. Graft vs Host Disease Mid Stage Products (Phase II)
8. Graft vs Host Disease Early Stage Products (Phase I)
9. Graft vs Host Disease Preclinical Stage Products
10. Graft vs Host Disease Therapeutics Assessment
11. Graft vs Host Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Graft vs Host Disease Key Companies
14. Graft vs Host Disease Key Products
15. Graft vs Host Disease Unmet Needs
16 . Graft vs Host Disease Market Drivers and Barriers
17. Graft vs Host Disease Future Perspectives and Conclusion
18. Graft vs Host Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
12 hours ago
- CTV News
Breakthrough revelead in sickle cell treatment options
Sickle cell disease is a genetic condition that affects hundreds of thousands of people round the world. Health reporter Pauline Chan details the latest development in treatment options.
Globe and Mail
16 hours ago
- Globe and Mail
Info-Tech LIVE 2025 Day 3 Highlights: Talent Strategies, the Future of AI and Quantum, and Key Takeaways From Final Day of Major IT Conference
The third and final day of Info-Tech LIVE 2025 in Las Vegas concluded the week by spotlighting bold leadership insights, forward-looking AI strategies, and transformative playbooks to guide IT organizations through exponential change over the coming year. TORONTO , June 13, 2025 /CNW/ - The final half-day of Info-Tech LIVE 2025 wrapped up with impactful keynotes focused on securing top talent, exploring groundbreaking technologies, and summarizing crucial insights gained over the course of the global research and advisory firm's annual conference. Thousands of IT leaders gathered at Bellagio in Las Vegas from June 10 to 12, 2025 , and received strategic guidance on harnessing emerging trends and fostering resilient organizations that are ready for future challenges. Together, these final keynotes distilled the spirit of Info-Tech LIVE 2025 in Las Vegas : future-ready leadership grounded in practical action. Whether redefining how to approach talent, embracing the frontier of quantum computing, or synthesizing the week's most essential insights, each session delivered tangible takeaways to help organizations move forward with purpose. Key Highlights From Info-Tech LIVE 2025 in Last Vegas Day 3: 1. The Race for Talent: Build Over Buy Speaker: Carlene McCubbin , AVP of Research Development, Info-Tech Research Group The final day's keynote addressed the persistent IT talent crisis, arguing that traditional approaches to talent, which focused heavily on hiring and certifications, are no longer viable in today's fast-evolving landscape. Despite rising expectations for IT to lead innovation, only a small percentage of organizations currently meet these demands, with staff capacity, skills, and engagement cited as the top pain points. To tackle these issues, Carlene McCubbin introduced the AI x Talent Flywheel, a compounding framework that helps organizations rethink and redesign their talent systems to match the pace of change. Key takeaways Automate to Reclaim Time: Eliminate low-value tasks and reinvest saved time into growth by using AI to "automate the friction." Embed Learning into Work: Shift from episodic training to continuous, embedded learning using the 60-30-10 rule: 60% in-flow learning, 30% peer intelligence, and 10% formal updates. Expand with AI Agents: Scale through centaur leadership models where AI and humans collaborate symbiotically, expanding output without additional headcount. Build the Human Advantage: Focus on adaptability, creativity, and empathy, traits AI can't replicate, to unlock performance and future-proof teams. 2. The Future of AI & Quantum: What to Expect Next Speaker: Felix Schmidt , CEO & Founder, GenAIus Inc. In this provocative keynote, Felix Schmidt explored the convergence of agentic AI and quantum computing and their transformative implications for businesses and society. Using vivid comparisons between classical and quantum computing, Schmidt showcased the radical capabilities of quantum chips, highlighting that problems that traditional supercomputers would take longer than the universe's age can now be solved in mere minutes. Schmidt introduced the concept of "Q Day," the moment quantum computing becomes publicly accessible, and emphasized the urgency of preparing for it. Schmidt warned that encryption methods, blockchain systems, and even national infrastructure could be at risk, urging IT leaders to audit their encryption and begin AI agentic pilots immediately. Key Takeaways: Quantum computing represents a paradigm shift, not just an upgrade, that can drastically outperform classical machines in both speed and scale. AI agents are already transforming enterprise operations, offering unprecedented productivity gains when deployed effectively. Executive digital twins are becoming a reality, streamlining workflows and redefining leadership efficiency. The acceleration toward "Q Day" demands that organizations start preparing now by piloting agentic AI, auditing encryption, and staying informed on quantum advancements. 3. Five Key Takeaways from Info-Tech LIVE 2025 Speaker: Jeremy Roberts , Senior Director, Research & Content, Info-Tech Research Group This closing keynote brought together the major themes of the conference, offering actionable insights to carry forward. Jeremy Roberts highlighted how IT leaders can seize the moment to lead with confidence and transform uncertainty into opportunity. Key takeaways Don't just survive; thrive. Uncontrollable external events will always occur, but bold leadership during times of uncertainty can turn crises into catalysts for progress . Organizations can't out-hire the pace of change; they must out-learn it. This means fostering continuous learning, building strong peer networks, and prioritizing a healthy workplace culture over quick fixes. IT must first get its own house in order. Structured frameworks, such as the CIO Playbook, enable IT departments to optimize their performance and support enterprise-wide growth. Make IT's value visible. If an impact isn't seen, it's as if it hasn't happened. Clearly linking metrics to business value ensures alignment with all stakeholders, from chief financial officers (CFOs) to chief executive officers (CEOs). AI agents are not plug-and-play. Effective implementation requires rigorous planning and prototyping to avoid the many technical, operational, and integration-related pitfalls. Media Access to Info-Tech LIVE 2025 For media inquiries, including requests for interviews with featured speakers and experts to discuss what has been launched and explored at LIVE 2025, or for access to session recordings and additional content, please contact pr@ For conference-related press releases and images, please visit the online Info-Tech LIVE 2025 Media Kit. About Info-Tech Research Group Info-Tech Research Group is one of the world's leading research and advisory firms, proudly serving over 30,000 IT and HR professionals. The company produces unbiased, highly relevant research and provides advisory services to help leaders make strategic, timely, and well-informed decisions. For nearly 30 years, Info-Tech has partnered closely with teams to provide them with everything they need, from actionable tools to analyst guidance, ensuring they deliver measurable results for their organizations. To learn more about Info-Tech's divisions, visit McLean & Company for HR research and advisory services and SoftwareReviews for software-buying insights. Media professionals can register for unrestricted access to research across IT, HR, and software and hundreds of industry analysts through the firm's Media Insiders program. To gain access, contact pr@ For information about Info-Tech Research Group or to access the latest research, visit and connect via LinkedIn and X. SOURCE Info-Tech Research Group
Globe and Mail
20 hours ago
- Globe and Mail
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graft vs Host Disease pipeline constitutes 45+ key companies continuously working towards developing 50+ Graft vs Host Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Graft vs Host Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graft vs Host Disease Market. The Graft vs Host Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Graft vs Host Disease Pipeline Report: Companies across the globe are diligently working toward developing novel Graft vs Host Disease treatment therapies with a considerable amount of success over the years. Graft vs Host Disease companies working in the treatment market are Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others, are developing therapies for the Graft vs Host Disease treatment Emerging Graft vs Host Disease therapies in the different phases of clinical trials are- ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others are expected to have a significant impact on the Graft vs Host Disease market in the coming years. In April 2025, The California Institute for Regenerative Medicine (CIRM) has granted $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103. This therapy aims to prevent graft-versus-host disease (GvHD) in blood cancer patients receiving mismatched stem cell transplants. TRX103 is an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to reduce transplant-related complications and improve patient outcomes. In March 2025, Orca Bio's investigational T-cell immunotherapy for blood cancers significantly improved outcomes, more than doubling the rate of patients who remained free from moderate-to-severe chronic graft-versus-host disease (GvHD). According to results from the Phase III Precision-T trial (NCT05316701), 78% of patients treated with Orca-T (TRGFT-201), the company's lead allogeneic T-cell therapy, were GvHD-free after one year, compared to only 38% in the group receiving standard allogeneic stem cell transplants. In January 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) aimed at improving survival outcomes in cancer patients through immune system modulation, has announced positive topline results from its pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter study conducted across Europe assessed the safety and efficacy of MaaT013 in patients with acute Graft-versus-Host Disease involving the gastrointestinal tract (GI-aGvHD) who are in third-line treatment — meaning they are resistant to steroids and either refractory or intolerant to ruxolitinib. The trial successfully achieved its primary endpoint, with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly surpassing the expected rate of 38%. These outcomes, evaluated by an Independent Review Committee (IRC), exceeded the predefined efficacy threshold and underscore the strong clinical potential of MaaT013 in treating third-line GI-aGvHD. In December 2024, The FDA has granted approval to Mesoblast's allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft versus host disease (GvHD) in pediatric patients aged two months and older. Significantly, this marks the first FDA-approved MSC-based therapy. The treatment will be commercially available under the brand name Ryoncil. Graft vs Host Disease Overview Graft versus Host Disease (GvHD) is a medical condition that can occur after a stem cell or bone marrow transplant, where the donor's immune cells (graft) recognize the recipient's body (host) as foreign and attack it. GvHD commonly affects the skin, liver, and gastrointestinal tract. It is classified into acute and chronic forms, with symptoms ranging from mild rashes and diarrhea to severe organ damage. Management typically involves immunosuppressive therapies to reduce the immune response. Emerging Graft vs Host Disease Drugs Under Different Phases of Clinical Development Include: ABSK021: Abbisko Therapeutics SYN-004: Theriva Biologics SER-155: Seres Therapeutics CB103: Cellestia Biotech Glasdegib: Pfizer TQ 05105: Chia Tai Tianqing Pharmaceutical RGI-2001: Regimmune Corporation Axatilimab: Syndax Pharmaceuticals MaaT013: MaaT Pharma MC 0518: Medac Itolizumab: Equillium Elranatamab: Pfizer Felzartamab: Janssen Pharmaceutical T-Guard: Xenikos MaaT013: MaaT Pharma Axatilimab: Syndax Pharmaceuticals TQ 05105: Chia Tai Tianqing Pharmaceutical Group Graft vs Host Disease Route of Administration Graft vs Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Intravenous Subcutaneous Graft vs Host Disease Molecule Type Graft vs Host Disease Products have been categorized under various Molecule types, such as Small molecule Cell Therapy Peptides Polymer Small molecule Gene therapy Graft vs Host Disease Pipeline Therapeutics Assessment Graft vs Host Disease Assessment by Product Type Graft vs Host Disease By Stage and Product Type Graft vs Host Disease Assessment by Route of Administration Graft vs Host Disease By Stage and Route of Administration Graft vs Host Disease Assessment by Molecule Type Graft vs Host Disease by Stage and Molecule Type DelveInsight's Graft vs Host Disease Report covers around 50+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Graft vs Host Disease product details are provided in the report. Download the Graft vs Host Disease pipeline report to learn more about the emerging Graft vs Host Disease therapies Some of the key companies in the Graft vs Host Disease Therapeutics Market include: Key companies developing therapies for Graft vs Host Disease are - Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology, AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others. Graft vs Host Disease Pipeline Analysis: The Graft vs Host Disease pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Graft vs Host Disease with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graft vs Host Disease Treatment. Graft vs Host Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Graft vs Host Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graft vs Host Disease market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Graft vs Host Disease Pipeline Market Drivers Increase in the number of patients suffering from chronic GvHD, robust Pipeline of GvHD are some of the important factors that are fueling the Graft vs Host Disease Market. Graft vs Host Disease Pipeline Market Barriers However, high cost of treatment, recognizing the limitations of currently available aGVHD therapies and other factors are creating obstacles in the Graft vs Host Disease Market growth. Scope of Graft vs Host Disease Pipeline Drug Insight Coverage: Global Key Graft vs Host Disease Companies: Abbisko Therapeutics, Theriva Biologics, Seres Therapeutics, Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharmaceutical, Regimmune Corporation, Syndax Pharmaceuticals, MaaT Pharma, Medac, Equillium, Xenikos, and others Key Graft vs Host Disease Therapies: ABSK021, SYN-004, SER-155, CB103, Glasdegib, TQ 05105, RGI-2001, Axatilimab, MaaT013, MC 0518, Itolizumab, T-Guard, and others Graft vs Host Disease Therapeutic Assessment: Graft vs Host Disease current marketed and Graft vs Host Disease emerging therapies Graft vs Host Disease Market Dynamics: Graft vs Host Disease market drivers and Graft vs Host Disease market barriers Table of Contents 1. Graft vs Host Disease Report Introduction 2. Graft vs Host Disease Executive Summary 3. Graft vs Host Disease Overview 4. Graft vs Host Disease- Analytical Perspective In-depth Commercial Assessment 5. Graft vs Host Disease Pipeline Therapeutics 6. Graft vs Host Disease Late Stage Products (Phase II/III) 7. Graft vs Host Disease Mid Stage Products (Phase II) 8. Graft vs Host Disease Early Stage Products (Phase I) 9. Graft vs Host Disease Preclinical Stage Products 10. Graft vs Host Disease Therapeutics Assessment 11. Graft vs Host Disease Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Graft vs Host Disease Key Companies 14. Graft vs Host Disease Key Products 15. Graft vs Host Disease Unmet Needs 16 . Graft vs Host Disease Market Drivers and Barriers 17. Graft vs Host Disease Future Perspectives and Conclusion 18. Graft vs Host Disease Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
